BMRA Biomerica
- 0.588
- -0.026-4.19%
- 0.575
- -0.013-2.21%
Biomerica News
Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE
Biomerica (BMRA) said Monday it has a multiyear exclusive distribution deal with an undisclosed health-care conglomerate in the United Arab Emirates, starting with an order for home tests for colorect
Biomerica Shares Are Trading Higher After the Company Announced an Exclusive Distribution Agreement With a UAW Healthcare Conglomerate.
Biomerica Shares Are Trading Higher After the Company Announced an Exclusive Distribution Agreement With a UAW Healthcare Conglomerate.
Biomerica Jumps on Signing Multi-year Distribution Deal With Major UAE Healthcare Company
Biomerica Announces Multi-Year Exclusive Distribution Agreement With A UAE Healthcare Conglomerate, Commencing With An Initial Order For EZ Detect And Aware Products
Biomerica Announces Multi-Year Exclusive Distribution Agreement With A UAE Healthcare Conglomerate, Commencing With An Initial Order For EZ Detect And Aware Products
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersSoligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. Longeveron (NASDAQ:LGVN) shares increased by 51.47
Biomerica Provides Update on InFoods IBS Expansion
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each
Reported Late Friday, Biomerica Q3 EPS $(0.11) Up From $(0.12) YoY, Sales $1.02M Down From $1.11M YoY
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.11) per share. This is a 8.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported $1.02 mil
Biomerica GAAP EPS of -$0.11, Revenue of $1M
Biomerica Reports Third Quarter 2024 Financial Results
Biomerica, Inc. (Nasdaq: BMRA), (the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024.
Biomerica (BMRA.US): The 2024 Q3 financial report achieved revenue of US$1.017 million, previous value of US$1,111 million; earnings per share were -0.11 USD, previous value of -0.12 USD.
Biomerica (BMRA.US): The 2024 Q3 financial report achieved revenue of US$1.017 million, previous value of US$1,111 million; earnings per share were -0.11 USD, previous value of -0.12 USD.
Biomerica Received Decision Grant European Patent Number EP3497447 Titled "COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING"
Biomerica Received Decision Grant European Patent Number EP3497447 Titled "COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING"
Biomerica InFoods IBS Data to Be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Collaborators at the University of Michigan will present new Data on InFoods IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical SessionIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomeric
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAinos (NASDAQ:AIMD) stock moved upwards by 54.3% to $1.62 during Friday's after-market session. The company's market cap stands at $7.5 million. Aadi Bioscience (NASDAQ:AADI) shares rose 38.54%
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersCardiff Oncology (NASDAQ:CRDF) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's market cap stands at $101.4 million. As per the press release, Q4 ear
Press Release: Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven t
Biomerica Has Received A Decision To Grant European Patent Number EP3449254 Titled "Compositions, Devices, And Methods Of Crohn's Disease Sensitivity Testing"
Biomerica Has Received A Decision To Grant European Patent Number EP3449254 Titled "Compositions, Devices, And Methods Of Crohn's Disease Sensitivity Testing"
Biomerica Reports Q2 Results
CORRECTION: Biomerica Reports Q2 2024 EPS $(0.09) Up From $(0.12) YoY, Revenue $1.6M Up From $1.5M YoY
CORRECTION: Biomerica Reports Q2 2024 EPS $(0.09) Up From $(0.12) YoY, Revenue $1.6M Up From $1.5M YoY
Biomerica 2Q Rev $1.6M >BMRA
Biomerica 2Q Rev $1.6M >BMRA
Biomerica Reports Second Quarter 2024 Financial Results
Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined
Analysis
Price Target
No Data
